Articles: Date 17-24
Tafenoquine - A new single dose drug for recurrent malarial human disease approved by US FDA
A new drug Tafenoquine to treat Malaria caused by mosquitos has been approved by USA Food and Drug Administration for general use after 60 years. It is specifically for the recurring form of malarial disease caused by Plasmodium Vivax which remains dormant in liver for may be many years and reawakening many times after. This type of malarial disease affects 8.5 million people each year and causes illness. It is manufactured by Glaxo Smith Kline (GSK) as brand name, Krintafel.
Date: 23-07-2018 02:20:50 UTC